Navigation Links
Cetero Research Leads Industry in Human Allergy Models
Date:5/25/2010

CARY, N.C., May 25 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), announced today that it has more Environmental Exposure Chambers (EECs), or allergy models for recreating environmental conditions than any other CRO. Over the past nine years, Cetero has used these models in more than 40 clinical studies to help its pharmaceutical partners develop novel therapies for a wide range of anti-allergic small molecule drugs, immunotherapies, biologics, and therapeutic devices.

Cetero's EECs can reliably reproduce peak allergy season year-round to test for seasonal allergies, including ragweed and grass and tree pollens, as well as perennial allergies including cat dander and dust mites. The allergy models can also be used for asthma and other conditions, such as conjunctival, nasal, and bronchial allergen challenges, and intracutaneous testing. The newest chamber can test for both non-allergic rhinoconjunctivitis and dry eye.

"We know how important it is to keep clinical trials on schedule. Waiting for ragweed season or a cold dry day can significantly delay a development program," said Dr. Troy McCall, CEO of Cetero Research. "Our validated EEC models guarantee stable, reliable conditions for testing a range of conditions all year-round. This is great news for the approximately 50 million Americans with allergies looking for improved treatments."

With the EECs, subjects are continuously monitored within the custom-built facilities by highly-trained staff, which means maximum compliance in symptom recording. The resulting high-symptom scores and lower variability maximize the sensitivity of the allergy models, requiring fewer patients to be tested to discern treatment efficacy. Furthermore, as the subjects are confined at Cetero's clinical facility, trained staff can accurately measure a number of objective ocular, nasal, and lung function variables and biomarkers, which is difficult to do when subjects rate their own symptoms from outside the controlled environment of Cetero's site.

"Cetero's allergy models, combined with our proven bioanalytical expertise and support from our Scientific Affairs team, offer incredible flexibility for our clients," said Dr. Murray Ducharme, Chief Science Officer for Cetero Research. "We can conduct elements of the study, such as program development consultation, method validation, sample analysis, or proof-of-concept studies. We can also offer complete turnkey studies, if that is what our clients want."

Cetero is the only CRO to have six EECs developed and fully validated for Good Clinical Practice (GCP)-compliant studies. Data from these allergy models are accepted by the U.S. Food and Drug Administration (FDA), the Canadian Therapeutic Products Directorate (TPD), Medicines Control Agency (MCA) in the United Kingdom, and the European Medicines Agency (EMEA), which makes the testing even more valuable for companies looking to sell their products worldwide.

"We know that pharmaceutical and medical device manufacturers are looking for ways to improve efficiencies while maintaining the highest quality standards," added Dr. Murray Ducharme. "The allergy model studies provide data from fewer patients in a more controlled setting that can be used in multiple jurisdictions. Importantly, Cetero can also provide hybrid studies that combine Phase I and proof-of-concept, offering even further efficiencies that can help companies manage timelines and bottom lines in clinical trials."

About Cetero Research

Cetero Research is an industry leading contract research organization (CRO) in early phase research services. With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies – more than any other CRO. Cetero's proven track record allows the company to provide flexible and high quality drug development services, and its time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. In addition, Cetero owns and operates a full-scale central laboratory supporting Phase I-IV clinical trials in North and South America. For more information, visit www.cetero.com, or call 877.7CETERO.


'/>"/>
SOURCE Cetero Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
2. Isis Pharmaceuticals to Present at the 2010 Citi Investment Research Global Health Care Conference
3. Medco to Present at the 2010 Citi Investment Research Global Health Care Conference
4. New Research: Kids Consumption of Chronic Medications on the Rise
5. Research Evaluating Effectiveness of Behavioral Counseling and Varenicline for Smoking Cessation Featured in the American Journal of Preventive Medicine
6. Turning the Page in HIV Prevention Research: An AIDS Vaccine is Possible — AVAC Examines The Way Forward
7. Xenon Announces Appointment of EVP, Research & Development
8. Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
9. CVS Caremark to Participate in the Citi Investment Research 2010 Food & Drug Retail Conference
10. SRI International Researchers Present Promising New Therapeutic for the Treatment of Multiple Myeloma
11. DNA Medicine Institute Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Deutschland und GERMANTOWN, Maryland ... Referenzdatensatz von Horizon bestätigt nachgewiesene ... s   QIAGEN N.V. ... Standard: QIA) gab heute die Ergänzung seines ... und Verifizierungsdaten bekannt, die die bewährte Genauigkeit ...
(Date:5/31/2016)... , Germany and ... -- QIAGEN N.V. (NASDAQ: QGEN ... extensive package consisting of a quality control set and ... System, reinforcing the proven accuracy of its next-generation sequencing ... training for laboratories. QIAGEN has incorporated the Horizon Discovery ...
(Date:5/31/2016)... 31, 2016 Diplomat Pharmacy, Inc. (NYSE: ... conversation slated for June 7, 2016, to take a closer ... noon to 1 p.m. ET, will focus on a man ... the road to wellness. The event is ... patients and health care professionals, talking about triumphs and the ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... , ... Like jewels in a crown, the multiple awards presented to Fayez ... Ontario’s leading day spa and one of Canada’s few accredited 5 Star Spas! ... to combine spa services with hair and beauty services and has resulted ...
(Date:5/31/2016)... ... , ... In his latest video, renowned AstroNumerologist Jesse Kalsi ... presidential candidate Donald Trump as an example, Kalsi describes the way AstroNumerology conveys ... adding numbers up,” says Kalsi. “It is about looking at each individual number, ...
(Date:5/31/2016)... Linda, CA (PRWEB) , ... May 31, 2016 , ... ... both a primary screening tool and as an orthogonal tool for RNAi hit validation. ... highly functional and specific guide RNAs—allows rapid generation of CRISPR RNA (crRNA) collections in ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The Greenburgh ... New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman ... country’s “modern medical money maelstrom.” , During the interview with Mr. Feiner that ...
(Date:5/31/2016)... ... 2016 , ... Advertising Age has recognized SourceLink, ... the tenth consecutive year as a Top 20 Marketing Services Agency. Final results ... eighteenth in the “U.S. CRM/Direct Marketing Agency” category. , Recent investments made ...
Breaking Medicine News(10 mins):